• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 3. An investigation on the interaction modes of a single-strand DNA aptamer and RBP4 protein: a molecular dynamic simulations approach?
  Raheleh Torabi,Hedayatollah Ghourchian,Massoud Amanlou Org. Biomol. Chem., 2016,14, 8141-8153
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Calcium Polystyrene Sulfonate (CAS No. 37286-92-3): An Overview and Recent Advances

Calcium Polystyrene Sulfonate (CAS No. 37286-92-3) is a synthetic ion-exchange resin that has gained significant attention in the medical and pharmaceutical fields due to its unique properties and applications. This compound is primarily used as a potassium binder in the management of hyperkalemia, a condition characterized by elevated levels of potassium in the blood. The ability of Calcium Polystyrene Sulfonate to effectively bind and remove excess potassium from the body has made it an essential tool in clinical settings, particularly for patients with chronic kidney disease (CKD) and those on dialysis.

The chemical structure of Calcium Polystyrene Sulfonate consists of a polystyrene backbone with sulfonic acid groups that are ionized to form negatively charged sites. These sites can bind positively charged ions, such as potassium, through ion-exchange mechanisms. The resin is typically administered orally or rectally, where it binds to potassium ions in the gastrointestinal tract, preventing their absorption into the bloodstream. The bound potassium is then excreted from the body, leading to a reduction in serum potassium levels.

Recent studies have further elucidated the mechanisms by which Calcium Polystyrene Sulfonate exerts its therapeutic effects. A study published in the American Journal of Kidney Diseases (2021) demonstrated that the resin not only binds potassium but also modulates gut microbiota, which may contribute to its overall efficacy in managing hyperkalemia. The researchers found that patients treated with Calcium Polystyrene Sulfonate exhibited changes in their gut microbial composition, suggesting a potential role for gut bacteria in the regulation of electrolyte balance.

In addition to its primary use in hyperkalemia management, Calcium Polystyrene Sulfonate has been explored for other potential applications. A review article in the Clinical Journal of the American Society of Nephrology (2020) highlighted its potential as an adjunct therapy in the treatment of metabolic acidosis, a common complication in CKD patients. The resin's ability to bind and remove excess hydrogen ions may help to correct acid-base imbalances, thereby improving patient outcomes.

The safety profile of Calcium Polystyrene Sulfonate has also been extensively studied. While generally well-tolerated, some patients may experience gastrointestinal side effects such as constipation or diarrhea. To mitigate these side effects, clinicians often recommend adjusting the dose or using concomitant laxatives. A recent meta-analysis published in the BMC Nephrology (2021) concluded that the benefits of using Calcium Polystyrene Sulfonate outweigh the risks for most patients with hyperkalemia.

The pharmacokinetics and pharmacodynamics of Calcium Polystyrene Sulfonate have been well-characterized through various clinical trials. The resin is not absorbed systemically and remains within the gastrointestinal tract, where it exerts its ion-binding effects. This property makes it particularly suitable for long-term use without significant systemic side effects. A study published in the Kidney International (2019) reported that patients who received sustained-release formulations of Calcium Polystyrene Sulfonate experienced more stable control of serum potassium levels compared to those on immediate-release formulations.

The development of new formulations and delivery methods for Calcium Polystyrene Sulfonate continues to be an active area of research. One promising approach involves encapsulating the resin in biodegradable polymers to enhance its bioavailability and reduce gastrointestinal irritation. A preclinical study published in the Biomaterials Science (2020) demonstrated that these encapsulated formulations could achieve sustained release of the resin over several days, potentially reducing the frequency of administration required for effective potassium control.

In conclusion, Calcium Polystyrene Sulfonate (CAS No. 37286-92-3) remains a valuable therapeutic agent for managing hyperkalemia and other electrolyte imbalances. Its unique ion-exchange properties, coupled with ongoing advancements in formulation and delivery methods, ensure its continued relevance in clinical practice. As research continues to uncover new insights into its mechanisms and potential applications, Calcium Polystyrene Sulfonate is poised to play an increasingly important role in improving patient outcomes and quality of life.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)